-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – OP-101 in Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD))
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - OP-101 in Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) report and make more profitable business decisions. How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Acetylcysteine Zidrimer in Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD))
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Acetylcysteine Zidrimer in Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Acetylcysteine Zidrimer in Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD))Drug Details:Acetylcysteine zidrimer (OP-101)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Allogeneic Donor-Derived T-Cells Transduced With Bivalent Lentiviral Vector (CD19/CD22-BBz) Chimeric Antigen Receptor (CAR) in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Allogeneic Donor-Derived T-Cells Transduced With Bivalent Lentiviral Vector (CD19/CD22-BBz) Chimeric Antigen Receptor (CAR) in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using...
-
Analyst Opinions
Car Rental Market Trends and Analysis by Traveler Types, Product Developments, Challenges, Opportunities and Case Studies, 2023 Update
Car Rental Market Trends Report Overview The car rental market size was $74.5 billion in 2022. The car rental sector has undergone a substantial transformation over the past few years. The rise in demand for rental cars can be attributed to technological advancements and evolving consumer preferences. Car Rental Market Outlook, 2022-2027 ($ Billion) Buy the Full Report for Additional Insights on the Car Rental Market Forecast Download a Free Report Sample The car rental market research report provides a...
-
Company Insights
Aon – Digital Transformation Strategies
Aon Digital Transformation Strategies Overview Aon has been focusing on using artificial intelligence, cloud, and big data to digitally transform its operations. The annual ICT spending of Aon was estimated at $511.8 million for 2023. A major share of this spending is earmarked for acquiring hardware, ICT services, and consulting services from vendors. Aon is a provider of professional services. The company, through its subsidiaries, offers a range of commercial risk solutions, reinsurance solutions, retirement solutions, health solutions, and data...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PXL-770 in Non-Alcoholic Steatohepatitis (NASH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PXL-770 in Non-Alcoholic Steatohepatitis (NASH) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.PXL-770 in Non-Alcoholic Steatohepatitis (NASH)Drug Details:PXL-770 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VK-0214 in Adrenomyeloneuropathy (AMN)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VK-0214 in Adrenomyeloneuropathy (AMN) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.VK-0214 in Adrenomyeloneuropathy (AMN)Drug Details: VK-0214 (formerly MB-10866) is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PXL-065 in Non-Alcoholic Steatohepatitis (NASH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PXL-065 in Non-Alcoholic Steatohepatitis (NASH) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.PXL-065 in Non-Alcoholic Steatohepatitis (NASH)Drug Details:PXL-065 is under development for the treatment...